Biological Characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a Selective Sphingosine Kinase-2 Inhibitor and Anticancer Agent
Figure 5
K145 accumulates and suppresses the S1P level.
A and B) U937 cells were treated with K145 at the indicated concentrations for 3 h and the levels of K145 and S1P were measured by ESI-MS/MS. C) HEK293 cells were treated with K145 (10 µM) for 2 h. Lipids were extracted and different chain length species of ceramide were determined by LC-ESI-MS/MS. Numbers indicate chain length followed by the number of double bonds in the fatty acid. Data are averages of triplicate determinations and are expressed as pmol lipid/106 cells. D) U937 cells were treated with or without K145 (10 µM) for 3 h and levels of C1P species were determined by ESI-MS/MS. E) U937 cells were treated with FTY720 (1 µM) in the absence or presence of indicated K145 for 3 h, then FTY720-P was measured by ESI-MS/MS. *P<0.05 compared to control.